R&D News | pharmaphorum

News

Lilly takes on Vertex in non-opioid pain with SiteOne buy

Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.

News

ASCO 25: Merus bispecific scores again in HNSCC

For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye.

News

Roche takes new antibiotic into phase 3 for 'urgent threat'

Roche is moving its antibiotic zosurabalpin into phase 3 for CRAB, potentially a big step forward in the fight against antimicrobial resistance.

News

ASCO 25: Can GLP-1 drugs reduce cancer risk?

A study has suggested the benefits of GLP-1 agonists could extend to a reduction in the risk of a slew of cancers associated with being overweight.

News

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

Jazz and PharmaMar have revealed the overall survival data with their small-cell lung cancer drug Zepzelca, described as a 'milestone' in the disease.

News

ASCO 25: Roche places Itovebi marker in breast cancer

Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.

Lilly takes on Vertex in non-opioid pain with SiteOne buy

ASCO 25: Merus bispecific scores again in HNSCC

Roche takes new antibiotic into phase 3 for 'urgent threat'

ASCO 25: Can GLP-1 drugs reduce cancer risk?

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

ASCO 25: Roche places Itovebi marker in breast cancer

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks